Exploratory analysis of EGFR FISH criteria in Japanese non-small cell lung cancer patients treated with gefitinib

被引：0
|
作者：
Kazuo, K.
Morrison, L. E.
Kimura, H.
Sone, T.
Araya, T.
Tamori, S.
Tanbo, Y.
Fujimura, M.
Speake, G.
Holloway, B. R.
机构：
[1] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[2] Abbott Mol Inc, Des Plaines, IL USA
[3] AstraZeneca, Macclesfield, Cheshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7599
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor
    Lee, H.
    Lee, K.
    Ahn, M.
    Hwang, H.
    Lee, J.
    Park, K.
    Kim, T.
    Yi, C.
    Chung, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Response to erlotinib after failure of gefitinib in non-small cell lung cancer with EGFR mutation
    Kim, H.
    Kim, Y.
    Oh, S.
    Seo, M.
    Lee, S.
    Kim, D.
    Heo, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Patients with Non-Small Cell Lung Cancer (NSCLC): Genome-Wide Analysis of Genetic Data
    Nyberg, Fredrik
    Barratt, Bryan
    Nakamura, Yusuke
    Kamatani, Naoyuki
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S25 - S26
  • [44] 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    Pallis, A. G.
    Voutsina, A.
    Kalikaki, Ar
    Souglakos, J.
    Briasoulis, E.
    Murray, S.
    Koutsopoulos, A.
    Tripaki, M.
    Stathopoulos, E.
    Mavroudis, D.
    Georgoulias, V.
    BRITISH JOURNAL OF CANCER, 2007, 97 (11) : 1560 - 1566
  • [45] ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    A G Pallis
    A Voutsina
    Ar Kalikaki
    J Souglakos
    E Briasoulis
    S Murray
    A Koutsopoulos
    M Tripaki
    E Stathopoulos
    D Mavroudis
    V Georgoulias
    British Journal of Cancer, 2007, 97 : 1560 - 1566
  • [46] Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
    Heon, Stephanie
    Yeap, Beow Y.
    Britt, Gregory J.
    Costa, Daniel B.
    Rabin, Michael S.
    Jackman, David M.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5873 - 5882
  • [47] Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib
    Kimura, H
    Kasahara, K
    Sekijima, M
    Tamura, T
    Nishio, K
    LUNG CANCER, 2005, 50 (03) : 393 - 399
  • [48] Management of patients with advanced non-small cell lung cancer: role of gefitinib
    Velcheti, Vamsidhar
    Morgensztern, Daniel
    Govindan, Ramaswamy
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 83 - 90
  • [49] The role of gefitinib in the management of Asian patients with non-small cell lung cancer
    Chang, Alex Y.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (03) : 401 - 411
  • [50] Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients
    Pircher, Andreas
    Ploner, Ferdinand
    Popper, Helmut
    Hilbe, Wolfgang
    LUNG CANCER, 2010, 69 (03) : 265 - 271
12345